GlassScriptPhysician profile
James R Trahan
NPI 1699863019
$2,888.40
in general payments reported to CMS, 2019-2025
30 companies · $406 in 2025
The $406 reported for 2025 was more than what a typical Psychiatry provider received nationally (typical 2025 total: $176).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $739 · 2020: $278 · 2021: $256 · 2022: $359 · 2023: $343 · 2024: $507 · 2025: $406.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $1,256.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $1,255.74 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Alkermes, INC. | $356.60 | 2019-2025 | Aristada, Lybalvi |
| Abbvie INC. | $285.79 | 2021-2025 | Vraylar |
| Otsuka America Pharmaceutical, INC. | $272.83 | 2019-2025 | Abilify Asimtufii, Rexulti, Nuedexta |
| Teva Pharmaceuticals USA, INC. | $185.59 | 2019-2025 | Austedo Xr, Uzedy, Austedo |
| Takeda Pharmaceuticals U.S.A., INC. | $181.21 | 2019-2024 | Trintellix |
| Iti, INC. (D/B/A Intra-Cellular Therapies, INC.) | $156.55 | 2021-2025 | Caplyta |
| Sunovion Pharmaceuticals INC. | $148.53 | 2019-2021 | |
| E.R. Squibb & Sons, L.L.C. | $124.83 | 2025 | Cobenfy |
| Janssen Pharmaceuticals, INC | $115.17 | 2019-2023 | Invega Sustenna, Spravato |
| Supernus Pharmaceuticals, INC. | $110.40 | 2022-2024 | Qelbree, Qelbree |
| Indivior INC. | $100.44 | 2019-2021 | |
| Allergan, INC. | $96.43 | 2019-2020 | |
| Jazz Pharmaceuticals INC. | $89.16 | 2019-2022 | |
| Neurocrine Biosciences, INC. | $83.59 | 2024-2025 | Ingrezza |
| Corium, LLC | $81.90 | 2022-2024 | Azstarys |
Show all 30 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Braeburn INC. | $53.92 | 2024 | Brixadi |
| Shire North American Group INC | $51.12 | 2019 | |
| Ironshore Pharmaceuticals INC. | $49.57 | 2019-2024 | |
| Vanda Pharmaceuticals INC. | $44.79 | 2019 | |
| Arbor Pharmaceuticals, INC. | $41.36 | 2019 | |
| Bausch Health US, LLC | $39.98 | 2022-2023 | Aplenzin, Wellbutrin |
| Alfasigma USA, INC. | $37.81 | 2022 | |
| Orexo US, INC. | $31.86 | 2019 | |
| Lundbeck LLC | $27.33 | 2024 | Rexulti |
| Vertical Pharmaceuticals, LLC | $24.98 | 2019 | |
| Axsome Therapeutics, INC. | $24.94 | 2024 | Sunosi |
| Merck Sharp & Dohme LLC | $23.95 | 2019-2022 | |
| Tris Pharma INC | $20.37 | 2022 | |
| Adlon Therapeutics L.P. | $13.76 | 2020 | |
| Noven Therapeutics, LLC | $13.64 | 2025 | Xelstrym |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw James Trahan listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.